New gene therapy aims to halt vision loss in rare eye disease
NCT ID NCT07002398
First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 26 times
Summary
This early-stage trial tests a gene therapy called VG801 for people with Stargardt disease, an inherited condition that causes progressive vision loss. The study will enroll 15 participants aged 6 and older who have confirmed ABCA4 gene mutations and poor vision in one eye. The goal is to check the safety of the treatment and see if it can help slow or stop further vision decline.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STARGARDT DISEASE 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, Shanghai Municipality, 200080, China
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.